Sat 17 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Phase 3,Randomized,Open-Label,Multicenter Study to Compare the Efficacy and Safety of BMS-986393,a GPRC5D-directed CAR-T Cell Therapy,Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma | Celgene Corporation | Ongoing | BMS-986393 | 3 | CA0881007 | 1.King Faisal Specialist Hospital and Research Center - Riyadh |
| A 52-week, multicenter, randomized, double-blind, placebo controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA) | Sanofi | Ongoing | Rilzabrutinib (SAR444671) | 3 | EFC17872 | 1.King Faisal Specialist Hospital and Research Center - Riyadh 2.Prince Mohammed bin Nasser Hospital - Jazan |
| A Real-World, International, MultICentre, Non-Interventional, Prospective CoHORt to Assess the Clinical and Patient-Reported Outcomes in Adults with MOderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated with Breztri/Trixeo (Budesonide /Glycopyrronium / Formoterol) in Routine Care Settings | PI initiated | Ongoing | Budesonide/ Glucopyrronim/ Formoteral | 4 | D5980R0012 | Abha Private Hospital (Asser) ,King Fahad Medical City (Riyadh), Fakeeh Hospital (Jeddah) |
| A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension | Crinetics Pharmaceutical/ Ebkar Consultancy | Ongoing | Atumelnant | 4 | CRN04894-13 | King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Non-Investigational Product, Multi Country Cohort Study to Describe the Long-Term Safety and Effectiveness of a Prior Single-Dose Treatment With Investigative Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Participants With Hemophilia A or Hemophilia B, Respectively | Pfizer Inc. | Ongoing | Giroctocogene Fitelparvovec and Fidanacogene Elaparvovec | 3 | C0371017 | King Faisal Specialist Hospital and Research Center (Riyadh),King Abdallah Medical City (Makkah) |
| A Real-world Multinational Observational Study to Determine Prevalence and Testing Patterns of Mutations in Patients with Hormone Receptor-positive Human Epidermal Growth Factor Receptor 2-negative Advanced or Metastatic Breast Cancer from the Gulf Cooperation Council Countries | AstraZeneca | Ongoing | Capivasertib / Fulvestrant/ Alpelisib | 4 | D133FR0026 | King Fahad Specialist Hospital (Dammam) |
| Comparative, Randomized, Multicenter, Followed by An Open Label Extension Trial in Patients with A Recent Acute Coronary Syndrome Evaluating the Early Inclusion of Inclisiran into Standard of Care Versus Standard of Care Alone in Kingdom of Saudi Arabia | Novartis | Ongoing | Inclisiran | 3 | CKJX839A1S | King Fahad Military Medical Complex (Dharan),King Fahad Armed Forces Hospital (Jeddah), King Fahad Medical City (Riyadh),Prince Sultan Cardiac Center (Riyadh) ,Saud Albabtin Cardiac Center (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxetecan in Patients with HRpositive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated with Endocrine Therapy (BEYOND) | AstraZeneca | Ongoing | Trastuzumab | 4 | D7814R0000 | King Saud University Medical City (Riyadh) |
| A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | ModernaTX, Inc./ Balsam CR | Ongoing | mRNA-3927 | 1/2 | mRNA-3927-P101-EXT | King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
| "A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults with Chronic Inflammatory Demyelinating Polyneuropathy" | Argenx BV/ Balsam | Ongoing | Empasiprubart (ARGX-117) | 3 | ARGX-117-2401 | King Faisal Specialist Hospital and Research Center (Riyadh) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.